Straits Times Index
3,323.47 -2.81 (-0.08%) Nikkei
39,726.39 +553.24 (+1.41%) Hang Seng
18,055.05 -17.85 (-0.10%) FTSE 100
8,247.79 -33.76 (-0.41%) Bitcoin USD
61,970.58 +1,147.16 (+1.89%) CMC Crypto 200
1,287.97 +38.85 (+3.11%)
Perspective Therapeutics, Inc. (CATX)
After hours:
| Previous close | 10.30 |
| Open | 10.20 |
| Bid | 9.62 x 900 |
| Ask | 9.60 x 900 |
| Day's range | 9.36 - 10.27 |
| 52-week range | 2.10 - 19.10 |
| Volume | |
| Avg. volume | 705,688 |
| Market cap | 643.808M |
| Beta (5Y monthly) | 1.43 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -1.70 |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 22.00 |
GlobeNewswirePerspective Therapeutics Announces Inclusion in the Russell 3000® Index
SEATTLE, June 12, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or “the Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today announced that it is set to join the broad-market Russell 3000 Index at the conclusion of the 2024 Russell US Indexes annual reconstitution, effective at the open of US equity markets on Monday, July 1st, according to an updated list of additions to
- GlobeNewswire
Perspective Therapeutics Announces 1-for-10 Reverse Stock Split
SEATTLE, June 11, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or “the Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today announced that it will effect a 1-for-10 reverse stock split, effective at 4:01 p.m. Eastern time on June 14, 2024. Beginning with the opening of trading on June 17, 2024, Perspective’s common stock is expected to begin trading on the NYSE American o
- GlobeNewswire
Perspective Therapeutics Presents at the Society of Nuclear Medicine and Molecular Imaging 2024 Annual Meeting
SEATTLE, June 10, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or “the Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today announced six updates featuring the Company’s alpha-particle radiopharmaceuticals at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2024 Annual Meeting, that was held on June 8-11, 2024, in Toronto Canada. “We are pleased with the accr
